Skip to content
★ Sign in to follow
CP

Chongqing Pharscin Pharmaceutical Co., Ltd. Stock: price and insider trades · China

华森制药

CN·Mcap CN¥6.2BHealth Care

No insider purchase over the last 90 days. The latest, by 邓志春, was filed 26 Apr 2023.

Chongqing Pharscin Pharmaceutical Co., Ltd.: what insiders have been doing

Every trade that managers of Chongqing Pharscin Pharmaceutical Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. Between 5 November 2025 and 5 November 2026, 1 insider published 3 filings.

The flow runs one way only: 3 sales worth €5.8M, from 1 insider, and no purchase. One trade stands out by size: a sale of €3.5M from 游洪涛, disclosed on 10 December 2025.

Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. Until a filing is published, the market cannot know about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

Across the 521 companies tracked on its exchange, the median is 2 filings; at 3 filings, this issuer sits above that mark. Over the whole record (from 2023), the tally stands at 1 purchase and 4 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
5
Thresholds
n/a
Buy Volume
€198
1 ops. · all time
Sell Volume
€6M
4 ops. · all time

Who traded when

BuySale
游洪涛3 sales
彭晓燕1 sale

Since the insiders bought

  • Filed 26 Apr 2023 · 1292 days ago · €198
    -16.1%
    Entry CN¥15.86 · Close at T+365 CN¥13.31

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 15,151 of 26,912 companies
47.8
score / 100
Value
29
Quality
66
FCF yld0.8%
Earn yld1.0%
EV/EBITDA37.8x
ROE3.4%
Gross mgn57%
Net mgn7.9%
Debt/EBITDA0.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥14.88
Analyst consensus
·
Income statement
RevenueCN¥827.1M
Gross profitCN¥474.7M57% margin
EBITDACN¥165.7M20% margin
Net incomeCN¥65.1M9.3% margin
Valuation
PER (trailing)82.7x
P/Book3.6x
Beta-0.22
Balance sheet & cash
Market capCN¥6.2B
Total debtCN¥41.8M
Free Cash FlowCN¥47.7M
Debt / Equity0%
Profitability & ownership
ROE3.4%
ROA1.7%
% insiders70.8%
% institutions2.1%
Last declaration on 13 January 2026
Declarations5 total
  • ▼
    董事,高管Executives
    17M CNY11SZSE
    1,200,600 shares35.8% of flowA股XSHESZSE:273000000111619400
  • ▼
    董事,高管Executives
    28M CNY13SZSE
    2,043,800 shares60.0% of flowA股XSHESZSE:273000000016474880
  • ▼
    董事,高管Executives
    2M CNY7SZSE
    138,000 shares4.2% of flowA股XSHESZSE:173000009853526600
  • ▼
    高管Executives
    53,889 CNY19SZSE
    3,300 shares100.0% of flowA股XSHESZSE:173000009113797980
  • ▲
    监事Executives
    1,515 CNY15SZSE
    100 shares100.0% of flowA股XSHESZSE:173000006536417760
    Canonical exit: 25 Jul 2023 (T+90)

5 of 5 declarations

About Chongqing Pharscin Pharmaceutical Co., Ltd.

华森制药 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of innovative medications.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations